Abigail Alford is a Senior Molecular Biologist in the Vaccine Technology Team at Epitopea Ltd. She spent 1.5 years engineering phage for anti-infective use at Phico Therapeutics before moving her career to mRNA vaccine design at Epitopea.

Abigail received her PhD in Molecular Microbiology from the University of East Anglia, UK researching the rapid synthetic production of anti-infectives using heterologous host systems in Actinomycetes at the John Innes Institute.

Her main focus is on leveraging synthetic biology and genetic design for the betterment of human health.